Nexalis Therapeutics Ltd (ASX:NX1) has disclosed the issue of 15,000,000 unlisted options with an exercise price of $0.15 and an expiry date of 30 September 2031, issued on 30 October 2026 as part of a transaction previously announced to the market via an Appendix 3B lodged on 30 October 2026.

Key Points

  • 15,000,000 unlisted options issued on 30 October 2026, exercisable at $0.15 and expiring 30 September 2031
  • The options were not issued for cash consideration
  • Consideration comprised settlement of funding received up to the date of cancellation under the previous funding facility, including cancellation of existing 38.4 million options exercisable at $0.025 expiring 31 December 2029
  • The new options convert into NX1 ordinary fully paid shares upon exercise and are not intended to be quoted on ASX
  • Following the issue, NX1 ordinary fully paid shares on issue total 253,037,323

Terms of the Unlisted Options Issued 30 October 2026

According to the filing, the 15,000,000 options form a new class of unquoted securities with an exercise price of AUD $0.15 per option and an expiry date of 30 September 2031. The options are denominated in Australian dollars and, upon exercise, will convert into NX1 ordinary fully paid shares. The filing states that all securities issued in this class rank equally in all respects from their issue date, and that ASX has confirmed the terms of the securities are appropriate and equitable under listing rule 6.1.

Non-Cash Consideration and Cancellation of Previous Options

The filing discloses that the 15,000,000 options were not issued for cash consideration. Instead, the consideration provided was the settlement of funding received up to the date of cancellation under the previous funding facility, which also included the cancellation of 38,400,000 existing options with an exercise price of $0.025 expiring 31 December 2029. The filing confirms that no further issues of securities are yet to take place to complete the transaction referred to in the previously lodged Appendix 3B, dated 30 October 2026.

Unquoted Securities on Issue Following the Transaction

Following the issue, the company's unquoted securities on issue comprise multiple classes, including 4,000,000 options expiring 14 December 2026 at $0.20, 23,154,603 options expiring 22 December 2027 at $0.042, 11,470,564 performance rights, 1,000,000 options expiring 7 July 2028 at $0.12, 500,000 options expiring 31 October 2028 at $0.12, 2,000,000 options expiring 3 June 2027 at $0.15, and the newly issued 15,000,000 unlisted options expiring 30 September 2031 at $0.15. The company's total quoted ordinary fully paid shares on issue stand at 253,037,323.